Psoriasiform Drug Eruption Secondary to Sorafenib: Case Series and Review of the Literature

Courtney J. Ensslin, MD; Pei-han Kao, MD; Ming-ying Wu, MD; Yao-yyu Chang, MD; Tseng-tong Kuo, MD, PhD; Chia-hsun Hsieh, MD, MS; Sen-yung Hsieh, MD, PhD; Chih-hsun Yang, MD; Lloyd S. Miller, MD, PhD

PRACTICE POINTS

• The use of targeted anticancer agents continues to expand. With this expansion, the number and type of cutaneous adverse events continues to increase.
• Although sorafenib is known to cause various dermatologic side effects, there are few reports of psoriasiform dermatitis.
• Increased awareness of sorafenib-induced psoriasiform dermatitis and its management is vital to prevent discontinuation of potentially life-saving anticancer therapy.

The expanded use of novel targeted anticancer agents such as sorafenib has revealed a growing spectrum of adverse cutaneous eruptions. We describe 3 patients with sorafenib-induced psoriasiform dermatitis and review the literature of only 10 other similar reported cases based on a search of PubMed, Web of Science, and American Society of Clinical Oncology abstracts using the terms psoriasis or psoriasiform dermatitis and sorafenib.1-10 We seek to increase awareness of this particular drug eruption in response to sorafenib and to describe potential effective treatment options, especially when sorafenib cannot be discontinued.

Case Reports

Patient 1—A 68-year-old man with chronic hepatitis B infection and hepatocellular carcinoma (HCC) was started on sorafenib 400 mg daily. After 2 months of treatment, he developed painful hyperkeratotic lesions on the bilateral palms and soles with formation of calluses and superficial blisters on an erythematous base that was consistent with hand-foot skin reaction (HFSR). He also had numerous erythematous thin papules and plaques with adherent white scale and yellow crust on the bilateral thighs, lower legs, forearms, dorsal hands, abdomen, back, and buttocks (Figure 1). He had no personal or family history of psoriasis, and blood tests were unremarkable. Histologic analysis of punch biopsies from the buttocks and right leg revealed focal parakeratosis with neutrophils and serous...
crust, acanthosis, mild spongiosis, and lymphocytes at the dermoepidermal junction and surrounding dermal vessels, consistent with psoriasiform dermatitis (Figure 2). Sorafenib was discontinued and the eruption began to resolve within a week. A lower dose of sorafenib (200 mg daily) was attempted and the psoriasiform eruption recurred.

**Patient 2**—An 82-year-old man with chronic hepatitis B infection and HCC with lung metastasis was treated with sorafenib 400 mg daily. One week after treatment, he developed painful, thick, erythematous lesions on acral surfaces, consistent with HFSR. The sorafenib dose was decreased to 200 mg daily and HFSR resolved. Four months later, he developed well-demarcated, erythematous, scaly plaques with peripheral pustules on the right thigh (Figure 3) and right shin. He had no personal or family history of psoriasis, and blood tests were unremarkable. Samples from the pustules were taken for bacterial culture and fungal stain, but both were negative. Histologic analysis of a punch biopsy from the right thigh revealed necrotic parakeratosis, spongiform pustules, mild acanthosis, and a perivascular lymphocytic infiltrate with many neutrophils in the dermis. These findings suggested a diagnosis of pustular psoriasis, pustular drug eruption, or acute generalized exanthematous pustulosis. Treatment was initiated with mometasone cream. The patient subsequently developed hemoptysis and ascites from sorafenib. Sorafenib was discontinued and his skin eruption gradually resolved.

**Patient 3**—A 45-year-old woman with history of acute myeloid leukemia (AML) was started on sorafenib 200 mg twice daily as part of a clinical pilot study to maintain remission following an allogeneic bone marrow transplant. Four months after beginning sorafenib, the patient developed multiple well-defined, erythematous, thin papules and plaques with overlying flaky white scale on the bilateral upper extremities and trunk and scattered on the bilateral upper thighs (Figure 4) along with abdominal pain. Her other medical history, physical findings, and laboratory results were unremarkable, and there was no personal or family history of psoriasis. Her oncologist suspected that the eruption and symptoms were due to sorafenib and reduced the dose to 200 mg daily. Histologic analysis of a punch biopsy specimen revealed subcorneal neutrophilic collections with mild spongiosis and mild perivascular inflammatory infiltrate composed of lymphocytes and neutrophils (Figure 5). Direct immunofluorescence was
negative for antibody or complement deposition. A bone marrow biopsy was negative for AML recurrence. The patient was continued on sorafenib to prevent AML recurrence, and she was started on triamcinolone cream 0.1% twice daily. Two weeks later, the eruption worsened and the patient was started on oral hydroxyzine for pruritus and narrowband UVB (NB-UVB) phototherapy 3 times a week. After 9 applications of NB-UVB phototherapy, there was complete resolution of the eruption.

**Comment**

Sorafenib is an oral tyrosine kinase inhibitor that blocks tumor cell proliferation and angiogenesis due to its activity against vascular endothelial growth factor (VEGF) receptor, platelet-derived growth factor receptor, stem cell growth factor receptor, and rapidly accelerated fibrosarcoma kinases. It is primarily used for the treatment of solid tumors, such as advanced renal cell carcinoma, unresectable HCC, and thyroid carcinoma, and more recently has been expanded for treatment of AML due to potential inhibition of FMS-like tyrosine kinase 3 receptor. Although dermatologic toxicity is a common adverse event during treatment with sorafenib, reports of psoriasiform drug eruptions are rare.

**Review of Cases**

—Based on our literature search, there are 10 previously reported cases of psoriasiform drug eruption secondary to sorafenib. Of the 13 total cases (including the 3 patients in this report), 7 patients had a history of psoriasis; most were middle-aged men; and the treatment with sorafenib was for solid tumors, primarily HCC with the exception of patient 3 from the current report who was treated for AML (Table). In all cases, the dose of sorafenib ranged from 200 to 800 mg daily. In 5 cases, HFSR preceded (as with patient 2 in the current report) or presented concurrently (as with patient 1 in the current report) with the onset of psoriasiform rash. Of the 13 total cases, patients with a history of psoriasis generally developed the eruption in a shorter period of time after starting sorafenib (eg, days to 2 months) compared to those without a history of psoriasis (eg, 2 to 9 months) (Table), suggesting that patients with preexisting psoriasis more rapidly developed the drug eruption than patients without a history. In these patients with a history of psoriasis, all had longstanding mild to moderate stable plaque psoriasis, with the exception of 1 case in which the type of psoriasis was not described (Table). The presentation of the drug eruption following sorafenib varied from psoriasiform drug eruption (5 patients, including patient 3), pustular psoriasis (5 patients, including patient 2), and plaque psoriasis (3 patients, including patient 1). Interestingly, 5 of 6 patients with a history of plaque psoriasis presented with pustular psoriasis or psoriasiform drug eruption after treatment with sorafenib. These results suggest a causal relationship between sorafenib and exacerbation of preexisting psoriasis.

In the 13 total cases, treatments included mid- to high-potency topical steroids (10 cases), UVB or NB-UVB phototherapy (7 cases), and discontinuation of sorafenib (10 cases) (Table). All of these treatments led to improvement of the eruption with the exception of 1 case in which hand involvement was recalcitrant to therapy. Of the 10 cases in which sorafenib was discontinued, rechallenge at a lower dose was performed in 6 cases (including patient 1) with recurrence of psoriasiform rash seen in 5 cases (including patient 1) (Table). These data strongly implicate sorafenib as the direct cause of psoriasiform drug eruption.
## Cases of Sorafenib-Associated Psoriasis

<table>
<thead>
<tr>
<th>Patient Age, y/Gender</th>
<th>Duration of Sorafenib Prior to Rash Onset</th>
<th>Dose of Sorafenib</th>
<th>Clinical Presentation</th>
<th>Treatment of Psoriasis</th>
<th>Sorafenib Discontinued</th>
<th>Clinical Response of Psoriasis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cases of Sorafenib-Induced Psoriasis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56/M(^1)</td>
<td>3 mo</td>
<td>400 mg twice daily</td>
<td>Plaque-type psoriasis</td>
<td>NB-UVB phototherapy</td>
<td>No</td>
<td>Complete remission</td>
</tr>
<tr>
<td>59/M(^2)</td>
<td>4 mo</td>
<td>400 mg twice daily</td>
<td>Psoriasiform drug eruption</td>
<td>Topical steroids, NB-UVB phototherapy</td>
<td>No</td>
<td>Improved</td>
</tr>
<tr>
<td>63/M(^3)</td>
<td>9 mo</td>
<td>400 mg twice daily</td>
<td>Psoriasiform drug eruption</td>
<td>Triamcinolone cream</td>
<td>Yes; restarted at lower dose without rash recurrence</td>
<td>Improved</td>
</tr>
<tr>
<td>68/M (current report)</td>
<td>2 mo</td>
<td>400 mg daily</td>
<td>Plaque-type psoriasis</td>
<td>None</td>
<td>Yes; restarted at lower dose with rash recurrence</td>
<td>Improved</td>
</tr>
<tr>
<td>82/M (current report)</td>
<td>4 mo</td>
<td>400 mg daily, lowered to 200 mg daily</td>
<td>Pustular psoriasis</td>
<td>Mometasone cream</td>
<td>Yes</td>
<td>Improved</td>
</tr>
<tr>
<td>45/F (current report)</td>
<td>4 mo</td>
<td>200 mg twice daily, lowered to 200 mg daily</td>
<td>Psoriasiform drug eruption</td>
<td>Triamcinolone cream, NB-UVB phototherapy, oral hydroxyzine</td>
<td>No</td>
<td>Complete remission</td>
</tr>
<tr>
<td><strong>Cases of Sorafenib-Exacerbated Psoriasis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>68/M(^4)</td>
<td>2 mo</td>
<td>200 mg daily</td>
<td>Pustular psoriasis</td>
<td>Topical steroid, topical vitamin D(_3), NB-UVB phototherapy</td>
<td>Yes; restarted at lower dose with rash recurrence</td>
<td>Improved</td>
</tr>
<tr>
<td>61/M(^5)</td>
<td>Within days</td>
<td>400 mg daily</td>
<td>Plaque-type psoriasis</td>
<td>Potent topical steroid with vitamin D(_3), NB-UVB phototherapy</td>
<td>Yes</td>
<td>Complete remission</td>
</tr>
<tr>
<td>69/M(^6)</td>
<td>10 d</td>
<td>400 mg twice daily</td>
<td>Psoriasiform drug eruption</td>
<td>Clobetasol propionate ointment, NB-UVB phototherapy</td>
<td>Yes; restarted at lower dose with rash recurrence</td>
<td>Improved</td>
</tr>
<tr>
<td>75/M(^7)</td>
<td>3 wk</td>
<td>400 mg daily</td>
<td>Pustular psoriasis</td>
<td>Potent topical steroid with vitamin D(_3)</td>
<td>Yes; restarted at lower dose with rash recurrence</td>
<td>Improved</td>
</tr>
<tr>
<td>59/M(^8)</td>
<td>6 d</td>
<td>200 mg daily</td>
<td>Annular pustular psoriasis</td>
<td>Potent topical steroid</td>
<td>Yes</td>
<td>Complete remission</td>
</tr>
<tr>
<td>56/M(^9)</td>
<td>1 mo</td>
<td>Unknown</td>
<td>Psoriasiform drug eruption</td>
<td>Mid-potency topical steroids, phototherapy</td>
<td>Yes; restarted at lower dose with rash recurrence</td>
<td>Partial improvement</td>
</tr>
<tr>
<td>73/M(^10)</td>
<td>7 d</td>
<td>400 mg daily</td>
<td>Pustular psoriasis</td>
<td>Topical steroids</td>
<td>Yes</td>
<td>Improved</td>
</tr>
</tbody>
</table>

Abbreviations: M, male; NB-UVB, narrowband UVB; F, female.
cause of these psoriasiform eruptions. In the 3 cases in which sorafenib was not discontinued (including patient 3), there was notable improvement of the eruption with NB-UVB phototherapy.1,2 Vascular endothelial growth factor is overexpressed on psoriatic keratinocytes, contributes to epidermal hyperplasia, and induces angiogenesis in the dermis.12 The development of psoriasiform eruptions in patients treated with sorafenib seems paradoxical, as this drug has been considered as potential therapy for psoriasis due to its ability to block VEGF receptor signaling. Indeed, an improvement of psoriasis has been reported in 1 case of a patient treated with sorafenib13 and in multiple patients with psoriasis treated with other VEGF antagonists (eg, bevacizumab).14 The underlying mechanisms by which sorafenib induced or exacerbated psoriasis are not entirely clear. Palmoplantar hyperkeratosis, keratosis pilaris–like eruption, multiple cysts, eruptive keratoacanthomas, and squamous cell carcinoma have been described in patients treated with sorafenib, supporting the hypothesis that treatment with sorafenib alters keratinocyte proliferation and differentiation.15 In addition, B-Raf inhibitors such as imatinib are known to induce or exacerbate psoriasiform dermatitis.16 The activity of sorafenib resulting in psoriasis may be specific to RAF kinase inhibition, as there are no reports in the literature that describe psoriasis in patients treated with sorafenib targets such as VEGF receptor, stem cell growth factor receptor, or platelet-derived growth factor receptor. Future studies are needed to fully elucidate the underlying mechanisms by which sorafenib induces or exacerbates psoriasiform dermatitis and whether the severity of the drug eruption correlates with the antitumor efficacy of sorafenib.

**Conclusion**

Although psoriasiform drug eruptions secondary to sorafenib are not life-threatening, they impact quality of life with associated pain, pruritus, infection, and limitation of daily activities. Dose reduction or discontinuation of sorafenib resulted in resolution of the psoriasiform dermatitis; however, as demonstrated in 3 cases (including patient 3),1,2 psoriasiform dermatitis can be managed while maintaining the patient on sorafenib so that treatment of the malignancy is not compromised.

**REFERENCES**